Protein CProtein SFree SAntithrombin IIILp(a)Lupus anticoagulant
Abnormal range<73%<63%<66%<80≥35positive
19 TT cases2/13
(15%)		0/11
(0%)		0/9
(0%)		1/13
(8%)		6/11
(55%)		5/15
(33%)
110
VTE-controls		21/105
(20%)
NS		12/104
(12%)
NS		24/85
(28%)
NS		3/102
(3%)
NS		12/71
(17%)
P=0.012		4/91
(4%)
P=0.003

  • *Dated cut point for RAPC low: < 2.0 (before January 1, 1999); < 1.94 (January 1, 19 99 to January 23, 2001); < 2.2 (January 23, 2001 to  March 25, 2004); < 2.1 (after March 25, 2004).

  • †Dated cut point for IgG high: ≥ 23  GPL (anticardiolipin G units) (before October 31, 2012); ≥ 15 (after November 1, 12).

  • ‡Dated cut point for IgM high: ≥ 10  MPL (anticardiolipin M units) (before April 30, 2012); ≥ 13 (after May 1, 12).

  • §Dated cut point for homocysteine high: ≥ 13.5  μmol/L (before March 20, 2005); ≥ 12 (March 21, 2005 to March 27, 2006); ≥ 10.4 (March 28, 2006 to April 14, 2008); ≥ 11.4 (April 15, 2008 to November 14, 2008); ≥ 15 (November 15, 2008 to December 2, 2014); ≥ 10.4 (after December 3, 2014).

  • ACLA,  anticardiolipin antibody; CC, wild  type normal; Factor V, Factor V Leiden mutation; Lp(a), lipoprotein (a); MTHFR C677T, A1298C, methylenetetrahydrofolate reductore; PAIG, plasminogen activator inhibitor gene; PAI-1, plasminogen activator inhibitor activity; Pro C, protein C antigen; Pro S, protein S antigen; PTG, prothrombin gene mutation; RAPC, resistance to activated protein C; TC, heterozygote  mutant; TT, homozygous  mutant; VTE, venous thromboembolism .